Observational Study on Subcutaneous Immunotherapy for Japanese Cedar Pollinosis in 2024: Comparison With 2019.

Authors

Otsuka Hirokuni, Okubo Kimihiro, Otsuka Kuninori, Gotoh Minoru

Published in

Immunity, inflammation and disease. Volume 14. Issue 11.

Abstract

In a 2019 observational cohort study, we showed that subcutaneous allergen immunotherapy (SCIT) reduced symptoms in the preseason and during the Japanese cedar pollinosis (JCP) season. SCIT reduced metachromatic cells (Mc) and eosinophils in nasal swabs in subjects with JCP. The current 2024 study is compared with our 2019 study, focusing on the two JCP seasons to determine whether SCIT could further reduce symptoms and the counts of these cells in nasal swabs, particularly in patients who had received SCIT for ≥ 5 years.
Thirty-three subjects with SCIT treatment for JCP and 53 subjects without SCIT in the 2019 season, and 30 subjects with SCIT treatment and 40 subjects without SCIT in the 2024 season, were interviewed in season in both years, and Mc and eosinophil counts were examined in nasal swabs.
In 2019, there was a significant difference between the 33 subject visits with SCIT and the 53 subjects without SCIT: p = 2.2 × 10^-5 for severity, p = 0.002 for Mc counts in nasal swabs, and p = 0.008 for eosinophil counts. In 2024, there was a significant difference between the 30 subject visits with SCIT and the 40 subjects without SCIT: p = 2.4 × 10^-8 for severity, p = 2.6 × 10^-6 for Mc counts in nasal swabs, and p = 2.7 × 10^-8 for eosinophil counts. The 13 cases investigated in both 2019 and 2024 that had been on SCIT continuously showed significantly improved outcomes in 2024, in comparison to those on shorter-duration SCIT treatment.
SCIT can be safely administered at the doses described below, and a 2024 study showed not only symptom relief but also a dramatic reduction in Mc and eosinophil counts in nasal swabs compared to a 2019 study.

PMID:
43023532
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.